Recent 8-K filings for AVLN

• August 12, 2026, 8:06 AM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Avalyn reports Q2 net loss $28.9M; completes MIST enrollment with 398 patients

  Net loss $28.9M in Q2 2026 vs $20.2M in Q2 2025; R&D $24.7M, G&A $6.6M.

• July 1, 2026, 5:20 PM ET other material materiality 0.50 neutral item 1.01item 9.01

  Avalyn Pharma expands Boston sublease by ~4,934 sq ft; lease payments rise ~$924k

  Expands subleased premises from ~8,774 to ~13,708 rentable square feet at 105 W First Street, Boston.

• June 17, 2026, 8:03 AM ET other material materiality 0.55 positive item 7.01item 9.01

  Avalyn completes Phase 2b MIST trial enrollment of 375 patients for inhaled pirfenidone in PPF; topline data H2 2027

  Completed target enrollment of 375 patients in Phase 2b MIST trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis (PPF).

• June 3, 2026, 7:25 AM ET earnings materiality 0.50 neutral item 2.02item 9.01 ◈ Earnings Releases

  Avalyn Pharma reports Q1 net loss of $26.9M; MIST Phase 2b enrollment on track

  Net loss of $26.9M in Q1 2026 vs $17.5M in Q1 2025; R&D expense rose to $22.9M.

• May 1, 2026, 7:59 PM ET other material materiality 0.25 neutral item 5.03item 9.01 ◈ Governance Changes ×2

  Avalyn Pharma adopts amended charter and bylaws upon IPO consummation

  Authorizes 500M voting common shares and 200M non-voting common shares.

Materiality & sentiment trend

Max materiality 0.60 · Median 0.50 · Most common event other_material

1 positive 0 negative 4 neutral

source · AVLN on sec.gov